Other Devices for Heart Failure – Cardiac Contractility Modulation (CCM)

Andrew Coats

Abstract


Substantial advances in the medical treatment of HFrEF have improved survival and cardiac function in these patients. However despite the use of optimal medical therapy (OMT) and the use of recommended devices in those in whom they are indicated, persistent symptoms limit activity and adversely affect lifestyle in a substantial number of patients. For these patients newer devices other than ICD and CRT may offer an improvement in symptoms and/or survival. This paper reviews the evidence for the use of CCM and discusses in which patients it may be considered as recommended in the recent guidelines. CCM is an established treatment in the management of moderate to severely symptomatic heart failure with reduced EF and normal QRS duration. CCM impulse delivery is associated with acute improvements in cardiac contractility. Chronic changes include reversion from fetal to adult gene expression profiles in the heart, improved calcium handling, restorative ventricular remodeling, and improved cardiac function. The recent 2016 ESC/HFA guidelines for the management of heart failure considered that most of these newer devices had insufficient clinical trial data for a formal recommendation, but in the case of one, cardiac contractility modulation (CCM) the guidelines describe CCM as being something to be considered in selected patients with HF. This is based on a demonstrated improvement in exercise tolerance (peak VO2) and quality of life (by Minnesota LWHF questionnaire, MLWHFQ) produced by CCM in an individual patient data meta- analysis of all the randomised controlled trials of CCM.

Keywords


Heart failure, Cardiac Contractility Modulation; Guidelines

Full Text:

447 HTML

References


Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González- Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 May 20. pii: ehw128. PMID: 27206819.

Giallauria F, Vigorito C, Piepoli MF, Stewart Coats AJ. Effects of cardiac contractility modulation by non- excitatory electrical stimulation on exercise capacity and quality of life: An individual patient’s data meta- analysis of randomized controlled trials. Int J Cardiol. 2014 Aug 1; 175(2): 352–7. doi:10.1016/j.ijcard.2014.06.005.

Shenkman HJ, Pampati V, Khandelwal AK, McKinnon J, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest. 2002; 122: 528–34.

Burkhoff D, Shemer I, Felzen B, Shimizu J, et al. Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. Heart failure reviews. 2001; 6: 27–34.

Lawo T, Borggrefe M, Butter C, Hindricks G, et al. Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. J Am Coll Cardiol. 2005; 46: 2229–36.

Pappone C, Rosanio S, Burkhoff D, Mika Y, et al. Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. The American journal of cardiology. 2002; 90: 1307–13.

Kadish A, Nademanee K, Volosin K, Krueger S, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011; 161: 329–337 e1–2.

Morita H, Suzuki G, Haddad W, Mika Y, et al. Long- term effects of non- excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs. European journal of heart failure. 2004; 6: 145–50.

Yu CM, Chan JY, Zhang Q, Yip GW, et al. Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. JACC Cardiovascular imaging. 2009; 2: 1341–9.

Imai M, Rastogi S, Gupta RC, Mishra S, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol. 2007; 49: 2120–8.

Butter C, Rastogi S, Minden HH, Meyhofer J, et al. Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol. 2008; 51: 1784–9.

Goliasch G, Khorsand A, Schutz M, Karanikas G, et al. The effect of device- based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure. European journal of nuclear medicine and molecular imaging. 2011; 39: 408–15.

Butter C, Wellnhofer E, Schlegl M, Winbeck G, et al. Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption. J Card Fail. 2007; 13: 137–42.

Borggrefe MM, Lawo T, Butter C, Schmidinger H, et al. Randomized, double blind study of non- excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008; 29: 1019–28.

Neelagaru SB, Sanchez JE, Lau SK, Greenberg SM, et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart rhythm : the official journal of the Heart Rhythm Society. 2006; 3: 1140–7.

Cazeau S, Leclercq C, Lavergne T, Walker S, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001; 344: 873–80.

Abraham WT, Fisher WG, Smith AL, DeLurgio DB, et al. Cardiac resynchronization in chronic heart failure. NEnglJMed. 2002; 346: 1845–1853.

Borggrefe M and Burkhoff D. Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure. European journal of heart failure. 2012; 14: 703–12.

Liu M, Fang F, Luo XX, Shlomo BH, et al. Improvement of long- term survival by cardiac contractility modulation in heart failure patients: A case- control study. International journal of cardiology. 2016; 206: 122–6.

Abraham WT, Nademanee K, Volosin K, et al. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail. 2011 Sep; 17(9): 710–7. doi:10.1016/j.cardfail.2011.05.006.

Abraham WT, Lindenfeld J, Reddy VY, Hasenfuss G, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. J Card Fail. 2015; 21: 16–23.

Schau T, Seifert M, Meyhofer J, Neuss M, et al. Long- term outcome of cardiac contractility modulation in patients with severe congestive heart failure. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2011; 13: 1436–44.

Kuschyk J, Roeger S, Schneider R, Streitner F, et al. Efficacy and survival in patients with cardiac contractility modulation: long- term single center experience in 81 patients. International journal of cardiology. 2015; 183: 76–81.

Kloppe A, Lawo T, Mijic D, Schiedat F, et al. Long- term survival with cardiac contractility modulation in patients with NYHA II or III. International journal of cardiology. 2016. Apr 15;209:291-5. doi: 10.1016/j.ijcard.2016.02.001.

McMurray JJ, Packer M, Desai AS, Gong J, et al. Angiotensin- neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993–1004.

Abraham WT, Burkhoff D, Rousso B, Morley D, et al. Favorable Long- term Mortality Profile in NYHA III/IV Patients Treated with Contractility Modulation (CCM). 2017. Eur. J of Heart Failure (poster, Florence meeting 2016)

Abi-Samra F and Gutterman D. Heart Fail Rev. 2016; 21(6): 645–660. 10.1007/s10741-016-9571-6

Shewan L.G., Coats A.J.S., Henein M. Requirements for Ethical Publishing in Biomedical Journals. International Cardiovascular Forum Journal. 2015;2:2. http://dx.doi.org/10.17987/icfj.v2i1.4




DOI: https://doi.org/10.17987/icfj.v10i0.447

Copyright (c) 2017 Andrew Coats

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.